论文部分内容阅读
作者在此项前瞻性随机对照试验中采用聚合酶链反应(PCR)技术评价了α-2b重组干扰素(rIFNα-2b)治疗HCV病毒血症的效果。 39例研究对象的血清转氨酶均超过正常值2倍持续6个月以上,经第二代ELISA测定血清抗-HCV阳性,PCR测定血清HCVRNA阳性,肝活检确诊为慢性肝炎。其中男24例、女15例,平均年龄51岁。慢性迁延性肝炎(CPH)9例,慢性活动性肝炎(CAH)25例、肝硬变5例,平均病程65个月(6～197个月)。
In this prospective randomized controlled trial, the authors used polymerase chain reaction (PCR) to evaluate the efficacy of interferon alfa-2b (rIFNα-2b) in the treatment of HCV viremia. Serum aminotransferases in all 39 subjects were more than 2 times normal for more than 6 months. Serum anti-HCV was detected by second-generation ELISA. Serum HCVRNA was positive by PCR and chronic hepatitis was confirmed by liver biopsy. There were 24 males and 15 females, with an average age of 51 years. There were 9 cases of chronic persistent hepatitis (CPH), 25 cases of chronic active hepatitis (CAH) and 5 cases of liver cirrhosis with an average course of 65 months (6 to 197 months).